Bonraybio Co., Ltd. (TPE:6955)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
165.00
-3.00 (-1.79%)
At close: Apr 17, 2026
Market Cap4.09B +44.6%
Revenue (ttm)306.31M +37.4%
Net Income102.51M +49.9%
EPS4.12 +37.3%
Shares Out24.80M
PE Ratio40.05
Forward PEn/a
Dividend1.50 (0.91%)
Ex-Dividend DateMar 19, 2026
Volume16,005
Average Volume10,815
Open169.00
Previous Close168.00
Day's Range162.50 - 169.00
52-Week Range120.44 - 186.96
Beta0.18
RSI47.99
Earnings DateMay 13, 2026

About Bonraybio

Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also provides consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X QC Reticles, X QC video tools, and X QC beads; sperm DNA fragmentation test kits; and S10 data consolidation software. Bonraybio Co., Ltd. was found... [Read more]

Sector Healthcare
Founded 2015
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6955
Full Company Profile

Financial Performance

In 2025, Bonraybio's revenue was 306.31 million, an increase of 37.43% compared to the previous year's 222.88 million. Earnings were 102.51 million, an increase of 49.94%.

Financial Statements